Articles tagged with Metastasis
Researchers developed nanoparticles to target liver sinusoidal endothelial cells with miR-20a, restoring normal behavior and reducing tumor growth. The study found an 80% reduction in liver metastasis caused by colon cancer, highlighting a potential complementary treatment strategy.
A new genomic classifier score predicts aggressive prostate cancer, potentially changing treatment guidelines. The model integrates gene expression biomarker risk scores into existing risk groups, increasing accuracy and confidence in treatment recommendations.
Researchers identified genetic patterns in primary and matched metastatic cancers, finding that cells often break away as a collection rather than spreading as a single cell. This insight may lead to better treatments or approaches to prevent its spread at the onset.
Researchers at Purdue University have created a lifelike cancer environment using polymer to better understand how drugs can stop its course. The 3D jet writer device produces polymer microtissues with pore sizes large enough for cells to enter, enabling the simulation of metastasis in mice.
Researchers found elevated mir-24-3p in breast cancer patients destined to metastasize despite best available therapy. High expression of mir-24-3p correlated with poor survival rate and specific gene expression signature in TCGA.
Researchers from DKFZ found that circulating cancer cells exhibit specific polarity, which helps them attach to endothelial cells and migrate into tissues. This discovery may help predict individual risk for metastasis and find therapies to reduce it.
Researchers found that repurposed leukemia drugs can inhibit the secretion of pro-metastatic cathepsins in melanoma. This is due to ABL kinases increasing activity, which regulates transcription factors and induces gene expression. The study also showed that approved leukemia drug inhibitors prevent metastasis.
A genetic variant of mutant p53 enhanced mitochondrial function, leading to increased tumor cell metabolism and poorer prognosis for breast cancer patients. The study found that this variant was associated with faster migration and higher ability to invade and metastasize in models of lung and bone metastasis.
ILC2 cells play a crucial role in preventing or slowing metastasis in lung and prostate cancer by unleashing the killing power of T-cells. Researchers have concluded that ILC2 cells may be a potent weapon in stopping cancer from spreading, offering potential treatment for blood-borne and solid tumours.
Researchers found that genes responsible for metastasis can also initiate primary tumour development, driven by the fly model Drosophila melanogaster. This discovery strengthens the notion that same genes can activate tumour growth and metastasis in some tumours.
The discovery reveals that the enzyme RIPK1 decreases mitochondrial numbers, leading to oxidative stress and potential cell death. This finding could lead to a new strategy for eliminating ECM-detached cancer cells and improving patient survival.
Researchers at Dana-Farber Cancer Institute have identified a specific mechanism by which estrogen receptor-positive breast cancers become resistant to standard therapies and metastasize. DNA mutations in the estrogen receptor gene cause tumors to grow even without estrogen, leading to treatment-resistant disease.
A phase 3 clinical trial showed apalutamide treatment significantly delayed metastasis development in men with prostate cancer resistant to standard therapy. The treatment also improved survival and reduced disease progression symptoms.
Researchers at The Scripps Research Institute (TSRI) have discovered that levels of a key protein called LTBP3 fuel the chain reaction leading to cancer spread. Lower LTBP3 levels are associated with better prognosis in patients with certain types of cancer, suggesting it as a potential 'upstream' drug target.
A recent study revealed that patients with inherited DNA repair mutations in metastatic prostate cancer can derive similar benefits from treatment with standard therapies as other patients. Ongoing research explores the potential potency of targeted therapy with PARP inhibitors, which may offer additional therapeutic options for these ...
A new algorithm provides a comprehensive guide to managing spinal metastases, integrating specialties and offering personalized treatment approaches. The algorithm focuses on spine-specific issues and incorporates popular treatment paths, including surgical decompression and stereotactic body radiotherapy.
The foundation grants nearly $4.1M to support innovative early career researchers and breakthrough scientists conducting basic and translational cancer research. The recipients receive funding to pursue novel projects, with the goal of making paradigm-shifting breakthroughs in cancer prevention, diagnosis, and treatment.
Researchers identified unique mitochondrial defects and alterations in metabolic gene expression associated with aggressive triple-negative breast cancers. The findings provide new molecular biomarkers to identify patients at risk for metastasis and offer potential therapeutic targets.
A recent study published in Nature revealed that gene duplication plays a crucial role in explaining the aggressiveness and early metastasis of pancreatic cancer. Researchers discovered that specific gene amplifications occur along various evolutionary pathways of the cancer, leading to tumor development.
International organizations IASLC and BTOG are partnering to spread awareness of revised lung cancer staging criteria. The new system takes effect this month and aims to provide better care for patients. Key findings highlight improved prognostic factors, tumor size measurements, and coding systems for lung cancers with multiple lesions.
A team of scientists has identified the protein kinase MSK1 as a key regulator of dormant or latent metastases in estrogen-positive breast cancer. The study found that tumors expressing MSK1 have a longer period of latency with no symptoms, reducing the risk of earlier relapse.
A team of researchers has discovered that chromosomal instability can cause cancer cells to leak DNA, leading to a chronic inflammatory response that enables their spread. This finding opens up new possibilities for targeting metastasis in cancer treatment.
Researchers at BIDMC found that high-fat diets can drive metastasis in prostate cancer by suppressing tumor suppressor genes. They identified a key environmental factor driving this process and discovered a potential drug to block it.
Scientists developed a method to analyze lymph node tissue, identifying patients with higher risk of secondary cancers. The study found that analyzing architectural features of cancer-free lymph nodes can help differentiate between patients at high and low risk of metastasis.
Researchers successfully identified pulmonary metastases in a patient with osteosarcoma, making it easier to locate tumors for resection. The technique utilizes targeted fluorescence and binds to specific molecular markers, allowing for the detection of small or hard-to-locate nodules.
Researchers have discovered a key cellular receptor involved in ovarian cancer metastasis, CXCR4, which can be targeted with inhibitors to reduce tumor cell dissemination. High expression of CXCR4 is associated with aggressive variants of the disease.
Researchers found that macrophages, which reside in healthy breast tissue, help early breast cancer cells leave the breast for other parts of the body. The study identified how macrophages and early cancer cells form a 'microenvironment of early dissemination' that can be targeted to prevent metastasis.
The new guidelines provide strategies for including patients with brain metastases in clinical trials, addressing the lack of data on drug effects in the brain. The approach includes three specific strategies based on initial understanding of a drug's possible activity in the brain.
A University of Hawaii Cancer Center researcher has identified a mechanism that drives cancer cells to move during metastasis. The study defines a signaling hub required for cancer cell movement, which may provide new therapeutic opportunities for brain tumors and other cancers.
Researchers have discovered that radiosurgery can be an effective treatment option for patients with four or more brain lesions, even when the number of deposits exceeds the traditional three-lesion threshold. The study found no significant difference in survival rates between patients treated with radiosurgery for 4-10 metastases and ...
Researchers at MUSC identified a mechanism that regulates signaling events leading to cell migration and metastasis. The study found that ceramide synthase 4 (CerS4) affects cell migration by disrupting the ability of cells to form focal points in primary cilia.
Researchers developed a simple MRI technique to analyze brain tumors, finding that immune reactive cells around the tumor are associated with longer patient survival. This non-invasive method could provide an easier way for doctors to prescribe the most appropriate cancer treatment.
Researchers found that low PUMA expression distinguishes stem-like cells in cancer patients who experienced tumor recurrence. Reducing PUMA restores metastasis in cultured cells, highlighting a possible Achilles heel in aggressive breast cancers.
A new drug approach targets breast cancer's stem-like cells, slowing their spread before metastasis occurs. Researchers found co-expression of integrin αvβ3 and Slug identifies these cells in up to 20% of primary breast cancers.
Researchers developed an antibody called 15D11 that blocks Jagged1, a molecule making it easier for breast cancer cells to metastasize to bone. The antibody allows chemotherapy to keep cancer at bay by eliminating the protective effect of rebuilders in bone tissue.
A Phase III trial led by MD Anderson Cancer Center found that talazoparib, a PARP inhibitor, extends progression-free survival and improves quality-of-life measures for patients with metastatic HER2-negative breast cancer and BRCA1/2 mutations. Talazoparib was associated with a 46% lower risk of progression compared to chemotherapy.
The IST Austria lab of Daria Siekhaus will explore the role of MFSD1 in metastasis in mice and humans. The project aims to understand its involvement in changes to proteins and their impact on metastasis.
Researchers at VIB-KU Leuven have identified Caveolin-1 as a key player in suppressing metastatic growth in lung tumors. By studying macrophages at metastasis sites, they revealed that upregulation of this protein hinders cancer progression.
A study by UMMS researchers has identified a protein called GDF6 as a primary role in metastatic melanoma, found to be expressed in 80% of human melanomas and correlated with increased melanoma growth and spread. The findings offer new therapeutic potential for treatment-resistant skin cancer.
Researchers focus on cell motility in cancer, a key characteristic of malignant tumors. They aim to control the motility of cells using existing drugs and develop new therapeutic strategies.
Researchers identified several lncRNAs linked to ovarian cancer, including DNM30S, which correlates with worse survival rates. Targeting these lncRNAs may represent a viable treatment strategy for ovarian cancer.
A new study confirms presence of Fusobacterium in liver metastases of colon cancer patients, correlating with tumor growth and colonization. The bacteria travels with metastatic tumor cells to distant organs, potentially aiding their colonization.
A team of researchers at UC San Diego discovered a specific gene module that predicts patient life expectancy and metastasis across nine cancer types. The study found that a constrained environment triggers the formation of blood vessel-like structures in tumor cells, leading to aggressive behavior.
A modified XELIRI regimen with reduced doses of irinotecan and capecitabine has been shown to be non-inferior to FOLFIRI in terms of overall survival. The treatment, combined with bevacizumab, demonstrated favourable tolerability and efficacy comparable to XELOX plus bevacizumab.
The ALEX study shows alectinib 600 mg is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. Progression-free survival was longer with alectinib compared to crizotinib in both Asian and non-Asian populations.
Researchers analyzed EGFR mutation status in blood and cerebrospinal fluid to identify relationship with neurological symptoms and leptomeningeal metastases. The study found higher rates of EGFR mutations in cerebrospinal fluid for patients with brain metastases, offering new non-invasive testing options.
A new study found that analyzing genetic variations in tumor tissues can help physicians make better treatment choices for patients with gastric and esophageal adenocarcinoma. The research suggests focusing on metastatic sites to improve outcomes.
Researchers developed a bone-targeted nanoparticle that delivers chemotherapy directly to bone lesions, reducing tumor size and pain. The targeted nanoparticles showed a strong burst release of cabazitaxel and increased binding to bone compared to non-targeted nanoparticles.
A UK study published in Scientific Reports has identified a novel cell signaling interaction that may prevent a key step in lung cancer progression. The research, conducted by the University of Kentucky, found that microRNA molecules can alter TGFβ activity and prevent epithelial-mesenchymal transition, a critical process in metastasis.
The Cleveland Clinic has been awarded a 5-year, $2.6 million grant from the National Cancer Institute to create innovative models of colorectal cancer. The project aims to better understand how the disease develops and spreads.
Researchers at the University of Basel have identified a microRNA that inhibits epithelial-mesenchymal transition (EMT), a process linked to tumor cell spread and metastasis. This discovery may lead to new treatment approaches for breast cancer.
Researchers discovered that cells retain properties from their previous environment for several days, known as mechanical memory. This property can aid in tumor invasion and metastasis. The study's findings may lead to new insights into the mechanisms behind cancer spread.
Research from Helmholtz Zentrum München reveals a new mechanism by which obesity fuels the growth of breast cancer. The enzyme ACC1 plays a central role in this process, and blocking its activity with an antibody treatment can halt this mechanism.
A study published in Lancet Oncology identified MAF amplification as a tool to stratify breast cancer patients for zoledronic acid treatment. In MAF-negative patients, the inclusion of zoledronic acid improved outcomes, while non-postmenopausal MAF-positive patients experienced increased adverse outcomes.
A new synthetic compound, E260, has been developed to target the energy generation system of cancer cells, inhibiting an enzyme that supports their survival and dissemination. This approach has shown promising results in treating mice with metastatic cancer, completely curing them with no toxic effects.
Lina Cui, a UNM Assistant Professor, is leading a large-scale research project to understand the chemistry of disease progression and its role in cancer metastasis. The goal is to develop diagnostic tools that target specific enzymes involved in disease spread.
Researchers at Notre Dame's Harper Cancer Research Institute have made a breakthrough in understanding how ovarian cancer cells spread throughout the body. They found that a specific membrane proteinase called MT1-MMP plays a crucial role in regulating the transition of cancer cells from floating to sticking phases.
A randomized phase II clinical trial found that adding consolidative stereotactic radiation therapy to chemotherapy significantly increased progression-free survival expectancy nearly tripling it for patients with limited metastatic disease. Treatment-related side effects were similar between the two treatment approaches.
A study found that vessel growth created by tumors can enhance immunotherapy effects against melanoma. The growth secreted chemokines that attracted T cells into the tumor environment, leading to long-lasting anti-tumor immunity.
Researchers led by Mauro Ferrari, Ph.D., develop injectable nanoparticle generator polymeric doxorubicin (iNPG-pDox) to target cancer cells in lungs and liver with limited toxicity. The therapy aims to improve long-term survival and quality of life for triple-negative breast cancer patients.